Linking an antitumor cell antibody with an antilymphocyte antibody produces a bifunctional
antibody that can redirect T lymphocytes to lyse tumor cells. Bifunctional antibodies that …

T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing
anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such «targeted cytolysis» requires …

A technology is described which combines the power of T lymphocytes in eliminating
unwanted cells and causing beneficial inflammatory reactions with the great advantages of …

Cytotoxic cells express specific receptors on their sur-faces by which they distinguish altered
or foreign cells from normal autologous cells. These receptors form multiple links to …

Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell
fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill …

Cellular cytotoxicity is mediated by receptors on the surfaces of cytotoxic cells (lysis
promoting receptors) which are specific for cell surface components on target cells. Such …

It has been known for some time that mammalian immune systems are capable of
eliminating large tumor burdens. Redirecting the immune response of a patient to an …

It has been well established that bispecific antibodies containing anti-T-cell receptor MAbs
crosslinked to anti-tumor MAbs induce T cells to lyse tumor cells, as measured in a 51Cr …

Effective cancer treatment requires the irreversible cessation of growth, or destruction of
cancer cells in vivo. Ideally, this antitumor effect should be directed selectively against the …

Advantages of T-cell-and antibody-based immunotherapy can be combined by grafting
cytotoxic T lymphocytes with chimeric receptors composed of antibody fragments (which …